Halozyme Therapeutics (HALO) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.55 -0.03%
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $24.01 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
- Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
